Trial Profile
A phase II study of nab-paclitaxef in patients with pretreated advanced non-small-cell lung cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Aug 2017
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 21 Aug 2017 Status changed from recruiting to discontinued.
- 10 Jul 2014 New trial record